此外，国内政策暖风频吹，也为华大智造的股价提供了有力支撑。12月5日，财政部最新发布的《通知》对国产品的定义和价格优势进行了明确和细化，并提出拟在政府采购活动中，给予本国产品相对于非本国产品20%的价格评审优惠。该项政策的出台，给测序仪企业提供了“国家定义”的新规，对于国产化程度较高的基因测序仪企业而言，有助于其拓宽市场空间，打破高端医疗器械依赖进口的僵局。同时，近日央行对股票回购增持专项再贷款工具的进一步升级等政策调整也为股市注入了更多的资金活力，进一步刺激股市热情。On December 10, BGI Genomics (688114.SH) opened at 54.38 yuan, reached a high of 54.88 yuan with a maximum increase of 7.19%, and closed at 53.50 yuan, rising 4.49% compared to the previous trading day, with a Turnover Ratio of 2.671%.
According to Wind data obtained by Zhitong Finance APP, on December 10, BGI Genomics (688114.SH) opened at 54.38 yuan, reached a high of 54.88 yuan with a maximum increase of 7.19%, and closed at 53.50 yuan, rising 4.49% compared to the previous trading day, with a Turnover Ratio of 2.671%. The active performance on the market today indicates an increase in market attention and confidence in BGI Genomics.
In terms of news, the rise in BGI Genomics' stock price today is mainly due to several Bullish factors. On December 7, the military committees of the USA Congress released the final agreement text of the NDAA for fiscal year 2025, without including the Biosecurity Bill. In the future, due to potential changes or retirements of the proposal's initiators, the legislative process remains challenging. This helps to enhance market confidence对于生物医药行业, alleviating some pressures faced by related biotechnology companies, thus boosting BGI Genomics.
In addition, the continuous favorable domestic policies have also provided strong support for the stock price of BGI Genomics. On December 5, the Ministry of Finance released a new notice that clarified and refined the definition and price advantages of domestic products, and proposed a 20% price evaluation discount for domestic products in government procurement activities compared to non-domestic products. The introduction of this policy provides a new regulation defined by the state for sequencing instrument companies, which helps high-degree domestic Gene Sequencing instrument companies to expand their market space, breaking the dependence of high-end medical instruments on imports. At the same time, recent upgrades of special relending tools for Share Buyback by the central bank have injected more liquidity into the stock market, further stimulating market enthusiasm.
Since the beginning of 2024, a series of external factors such as market panic regarding the Bio Bill and concerns over weak domestic demand led the company's stock price to experience significant declines. With the further removal of international market obstacles and the introduction of favorable domestic market policies, BGI Genomics is expected to gradually increase its market share globally, and its valuation is likely to gradually recover. According to statistics from Bidy Tender Network, in the first three quarters, BGI Genomics held a leading position with a 55.05% market share in Gene Sequencing instruments.